BRAF and neoplasm: Since its identification from a Plexxikon structure-based drug discovery design [110], numerous studies have reported its potent activity as a selective inhibitor for BRAF V600 but not for wild-type BRAF cell lines [112], achieving cell-cycle arrest and apoptosis as well as tumor reduction in xenograft models of melanoma.